Mesenchymal stromal/stem cells markers in the human bone marrow

Rasini, Valeria; Dominici, Massimo; Kluba, Torsten; Siegel, Georg; Lusenti, Giulia; Northoff, Hinnak; Horwitz, Edwin M.; Schäfer, Richard

doi:10.1016/j.jcyt.2012.11.009

Cited by 100 publications

(96 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cells were found to represent a heterogeneous cell population, most of them constitutively expressing PDGFR and CD10 but variably expressing alpha-SMA, c-kit, Oct4 and CD68 [40]. The expression of CD10 in MSCs was reported either positive, or negative [5,14,22,28,33]. In the present study, the CD10 expression in the mammary samples was heterogeneous, positive or negative, as compared with the homogenous expression of CD34.…”

Section: Discussionmentioning

confidence: 41%

Telocytes of the mammary gland stroma

Petre

Rusu²,

Pop

et al. 2016

Folia Morphol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 41%

Telocytes of the mammary gland stroma

Petre

Rusu²,

Pop

et al. 2016

Folia Morphol

View full text Add to dashboard Cite

show abstract

“…In the human bone and BM, which are currently a major source for MSC therapeutics (table 1), MSC subpopulations, such as fibroblastoid reticular stromal cells, adipose stromal cells, round stromal cells and bone lining cells, reside in distinct microanatomical localizations [30]. In addition, the perivascular niche harbors cells featuring MSC phenotypes as shown for various organs [4,30,31].…”

Section: The Heterogeneity Of Mscs and Non-standardized Ex Vivo Cultumentioning

confidence: 99%

“…In addition, the perivascular niche harbors cells featuring MSC phenotypes as shown for various organs [4,30,31]. Due to the low frequency of MSCs in the BM (below 0.1% of nucleated cells [32]), manufacturing substantial numbers of MSC doses for therapeutic applications requires isolation/enrichment of MSCs as well as their in vitro expansion.…”

Section: The Heterogeneity Of Mscs and Non-standardized Ex Vivo Cultumentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy

Schäfer

Spohn

Baer

2016

Transfus Med Hemother

Self Cite

107

126

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are becoming increasingly important for the development of cell therapeutics in regenerative medicine. Featuring immunomodulatory potential as well as secreting a variety of trophic factors, MSCs showed remarkable therapeutic effects in numerous preclinical disease models. However, sustainable translation of MSC therapies to the clinic is hampered by heterogeneity of MSCs and non-standardized in vitro culture technologies. Moreover, potent MSC therapeutics require MSCs with maximum regenerative capacity. There is growing evidence that in vitro preconditioning strategies of MSCs can optimize their therapeutic potential. In the following we will discuss achievements and challenges of the development of MSC therapies in regenerative medicine highlighting specific in vitro preconditioning strategies prior to cell transplantation to increase their therapeutic efficacy.

show abstract

“…It is also expressed abundantly in retinoblastoma tumour cells, so it was used as a suitable marker for identification of suspicious tumour cells in the bone marrow or cerebrospinal fluid of affected patients (Seeger 2011;Laurent et al 2013). However, low levels of GD2 expression in some normal tissues such as the peripheral nerves, neurons (Mennel et al 1992), skin melanocytes (Hersey 1991) and bone marrow stem cells (Rasini et al 2013) limit the widespread use of this antigen for delivering targeted therapy to the eye because of anticipated toxicity, as evident when used for immunotherapy of neuroblastoma (Sorkin et al 2010).…”

Section: Introductionmentioning

confidence: 99%

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Torbidoni

Scursoni

Camarero

et al. 2014

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Introduction: The identification of molecules expressed selectively on the surface of retinoblastoma cells would allow applying targeted therapies. The Ganglioside, N-Glycolyl-GM3 (NeuGc-GM3), is an attractive candidate, as it has been detected in other paediatric neuroectodermic tumours, and it is not expressed in human normal tissues. The 14F7 antibody recognizes specifically the ganglioside NeuGc-GM3. Purpose: To characterize the expression of NeuGc-GM3 in retinoblastoma cell lines and in retinoblastoma tumours using the 14F7 monoclonal antibody. Methods: We studied WERI-Rb1 and Y79 cell lines, 24 retinoblastoma primary tumours from unilateral and bilateral cases and two bone marrow biopsies from metastatic retinoblastoma. Tumours were classified into three groups: non-invasive (n = 13), invasive (n = 9) and metastatic (n = 2). Three eyes enucleated because of non-tumoural conditions were used as controls. Cell lines and tumour sections were studied by immunohistochemistry using the 14F7 antibody. NeuGc-GM3 expression was evaluated by analysing the percentage of positive tumoural cells and the staining intensity. These parameters were analysed comparatively among the three groups. Results: Both retinoblastoma cell lines showed immunoreactivity to NeuGc-GM3 but WERI-Rb1 presented higher intensity than Y79. All the tumours studied showed strong immunoreactivity to NeuGc-GM3 with no significant differences among groups. In both bone marrow specimens, NeuGc-GM3 immunoreactivity was observed in retinoblastoma cells. In bilaterally enucleated cases, NeuGc-GM3 immunoreactivity was not altered before and after chemotherapy. Non-tumoural retinas were negative. Conclusions: NeuGc-GM3 is highly expressed in retinoblastoma cell lines, tumours and metastatic cells to the bone marrow, and it is not detectable in control eyes. There were no significant differences in the immunoreactivity to 14F7 among tumours from different disease stages. Its immunoreactivity did not change after chemotherapy.

show abstract

Mesenchymal stromal/stem cells markers in the human bone marrow

Cited by 100 publications

References 54 publications

Telocytes of the mammary gland stroma

Telocytes of the mammary gland stroma

Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Contact Info

Product

Resources

About